Role of 5-HT2A receptor antagonists in the treatment of insomnia

  title={Role of 5-HT2A receptor antagonists in the treatment of insomnia},
  author={Kimberly E. Vanover and Robert E Davis},
  journal={Nature and Science of Sleep},
  pages={139 - 150}
Insomnia encompasses a difficulty in falling asleep (sleep-onset insomnia) and/or a difficulty in staying asleep (SMI). Several selective serotonin-2A (5-HT2A) receptor antagonists have been in development as potential treatments for SMI. However, none have shown a sufficiently robust benefit-to-risk ratio, and none have reached market approval. We review the role of the 5-HT2A mechanism in sleep, the preclinical and clinical data supporting a role for 5-HT2A receptor antagonism in improving… 

Figures and Tables from this paper

Selective Serotonin 5-HT2A Receptor Antagonists and Inverse Agonists Specifically Promote Slow Wave Sleep (Stage N3) in Man
It is proposed that the co-administration of a selective 5-HT2A receptor antagonist or inverse agonist along with a hypnotic drug could be a valid clinical strategy for normalizing sleep induction and maintenance and for promoting N3 sleep in patients with an insomnia disorder.
The Effects of Benzodiazepine and Nonbenzodiazepine Agents, Ramelteon, Low-dose Doxepin, Suvorexant, and Selective Serotonin 5-HT2A Receptor Antagonists and Inverse Agonists on Sleep and Wakefulness
Evidence is suggested that the coadministration of a selective 5-HT2A receptor antagonist or inverse agonist with a hypnotic drug could be a valid clinical strategy for normalizing sleep induction and maintenance and for promoting N3 sleep in patients with insomnia disorder.
Serotonin Receptors for Treatment of Insomnia
Insomnia is the most common disorder characterized by symptoms such as difficulty in falling asleep and/or staying asleep, and abnormalities in quality and quantity of sleep, resulting in serious impairments in daytime activities.
Wake up to insomnia: future approaches to the management of insomnia
In the first full year of publication, the Nature and Science of Sleep has published a set of articles that begins to examine the advantages and limitations of a number of relatively novel pharmacological and behavioral therapies for insomnia, to help clinicians appraise new therapies, better manage insomnia, and identify important gaps in knowledge and promising future approaches.
Adjunctive brexpiprazole for the treatment of major depressive disorder
The tolerability of brexpiprazole is promising with relatively low rates of side effects and discontinuation rates, thus establishing it as a new option for the treatment of depression.
Psilocin acutely disrupts sleep and affects local but not global sleep homeostasis in laboratory mice
It is concluded that psilocin affects both global vigilance state control and local sleep homeostasis, an effect which may be relevant for its antidepressant efficacy.
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
The combination of in vitro and in vivo activities of this compound support its development for the treatment of schizophrenia and other psychiatric and neurologic disorders.
5-HT2A/2C receptor modulation of absence seizures and characterization of the GHB-model
The main result was that GHB-elicited ASs can be distinguished at the level of both EEG and behaviour, and spectral coherence can be used in different experimental models of ASs to characterize SWDs according to their waveform regularity.


APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia.
APD125 produced statistically significant improvements in objective parameters of sleep maintenance and sleep consolidation and was well tolerated in adults with primary chronic insomnia.
5-HT2 receptor antagonism and slow-wave sleep in major depression.
The effects of a single dose or ritanserin (5 mg) on sleep electroencephalography in 18 major depressed patients and in 10 control subjects were explored, in agreement with a potential 5-HT disturbance, particularly at the 5- HT2 receptor level, in some clinical forms of depression.
Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats.
A role for 5-HT2A receptor modulation in NREM sleep is suggested and a previously unrecognized role for5-HT6 receptors in sleep-wake regulation is suggested.
RP 62203, a 5-hydroxytryptamine2 antagonist, enhances deep NREM sleep in rats.
Following RP 62203 administration, the duration of deep nonrapid eye movement (NREM) sleep was found to increase at the expense of wakefulness in a dose-dependent manner, providing further evidence for the involvement of 5-HT2 receptors in the regulation of NREM sleep in rats.
Pharmacologic management of insomnia.
  • J. Walsh
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2004
Pharmacotherapy is indicated for many types of insomnia, most notably transient insomnia associated with stress, acute illness, or jet lag, and sedating antidepressants are frequently prescribed to promote sleep despite inadequate data to support their efficacy for this indication and a greater potential for clinically troublesome side effects.
Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine2A Inverse Agonist for the Treatment of Insomnia
All doses of nelotanserin significantly improved measures of sleep consolidation, including decreases in the number of stage shifts, number of awakenings after sleep onset, microarousal index, and number of sleep bouts, concomitant with increases in sleep bout duration.
Effects of ritanserin on sleep disturbances of dysthymic patients
Ritanserin significantly increased Slow Wave Sleep and changed the frequency and distribution of some stage transitions during the night and no other sleep parameters were modified by ritanerin treatment.
Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat
The hypothesis that the serotonergic system plays an active role in the regulation of the sleep-wakefulness cycle in the rat and that 5-HT2 receptors are involved in this action is supported.